JP2021523214A5 - - Google Patents

Info

Publication number
JP2021523214A5
JP2021523214A5 JP2020564676A JP2020564676A JP2021523214A5 JP 2021523214 A5 JP2021523214 A5 JP 2021523214A5 JP 2020564676 A JP2020564676 A JP 2020564676A JP 2020564676 A JP2020564676 A JP 2020564676A JP 2021523214 A5 JP2021523214 A5 JP 2021523214A5
Authority
JP
Japan
Prior art keywords
composition according
pcsk9
approximately
fusion protein
unit dose
Prior art date
Application number
JP2020564676A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019222529A5 (https=
JP7515406B2 (ja
JP2021523214A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/032710 external-priority patent/WO2019222529A1/en
Publication of JP2021523214A publication Critical patent/JP2021523214A/ja
Publication of JPWO2019222529A5 publication Critical patent/JPWO2019222529A5/ja
Publication of JP2021523214A5 publication Critical patent/JP2021523214A5/ja
Application granted granted Critical
Publication of JP7515406B2 publication Critical patent/JP7515406B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020564676A 2018-05-16 2019-05-16 Ｐｃｓｋ９結合分子を含む組成物及びその使用方法 Active JP7515406B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862672187P 2018-05-16 2018-05-16
US62/672,187 2018-05-16
PCT/US2019/032710 WO2019222529A1 (en) 2018-05-16 2019-05-16 Compositions comprising pcsk9-binding molecules and methods of use

Publications (4)

Publication Number Publication Date
JP2021523214A JP2021523214A (ja) 2021-09-02
JPWO2019222529A5 JPWO2019222529A5 (https=) 2022-05-20
JP2021523214A5 true JP2021523214A5 (https=) 2022-05-20
JP7515406B2 JP7515406B2 (ja) 2024-07-12

Family

ID=68540981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020564676A Active JP7515406B2 (ja) 2018-05-16 2019-05-16 Ｐｃｓｋ９結合分子を含む組成物及びその使用方法

Country Status (15)

Country Link
US (3) US10738102B2 (https=)
EP (1) EP3793612A4 (https=)
JP (1) JP7515406B2 (https=)
KR (1) KR20210010890A (https=)
CN (2) CN112423790B (https=)
AU (1) AU2019269617B2 (https=)
BR (1) BR112020023344A2 (https=)
CA (1) CA3115341A1 (https=)
EA (1) EA202092778A1 (https=)
IL (1) IL278710B2 (https=)
MX (1) MX2020012214A (https=)
SG (1) SG11202011304QA (https=)
UA (1) UA130399C2 (https=)
WO (1) WO2019222529A1 (https=)
ZA (1) ZA202007107B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3115341A1 (en) * 2018-05-16 2019-11-21 Lib Therapeutics, Llc Compositions comprising pcsk9-binding molecules and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932268B2 (en) * 2004-03-05 2011-04-26 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
US9994923B2 (en) * 2008-04-23 2018-06-12 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 (PCSK9) variants and uses thereof
EA022983B1 (ru) * 2010-04-13 2016-04-29 Бристол-Майерс Сквибб Компани Белки на основе структурного домена фибронектина, связывающие pcsk9
PL3395836T3 (pl) * 2011-01-28 2021-12-13 Sanofi Biotechnology Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
US9255154B2 (en) * 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US20160152686A1 (en) * 2013-03-13 2016-06-02 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
HK1213194A1 (zh) * 2013-03-14 2016-06-30 Daiichi Sankyo Co., Ltd. 用於新型的结合蛋白质pcsk9
EP3129401B1 (en) * 2014-03-20 2019-06-12 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type iii domains
CN106795214B (zh) * 2014-03-20 2022-09-02 百时美施贵宝公司 稳定化的基于纤连蛋白的支架分子
EP3842451A1 (en) 2015-03-12 2021-06-30 MedImmune, LLC Method of purifying albumin-fusion proteins
CA3115341A1 (en) * 2018-05-16 2019-11-21 Lib Therapeutics, Llc Compositions comprising pcsk9-binding molecules and methods of use
CN117580583A (zh) * 2021-06-25 2024-02-20 甘李药业股份有限公司 Pcsk9抑制剂和glp-1受体激动剂的药物组合

Similar Documents

Publication Publication Date Title
US8975223B2 (en) Methods for treating metabolic disorders and obesity with a peptide comprising the amino acid sequence of SEQ ID No. 146
CN103402545B (zh) 疏水性经修饰肽及其在肝特异性靶向中的用途
CA2959465C (en) Combination therapy of hbv and hdv infection
JP2020506693A5 (https=)
CN106456717A (zh) 速效胰岛素组合物
JP7672677B2 (ja) 全用量条件下でｂ型肝炎ウイルス関連肝疾患を治療する医薬品および方法
JP2021523214A5 (https=)
US12551541B2 (en) Albumin bound macromolecule tri-agonist activating GLP 1/GIP/glucagon receptors and methods therefor
JP2019520341A (ja) 代謝疾患を治療する組成物と方法
JPWO2019222529A5 (https=)
US20230295270A1 (en) Compositions comprising pcsk9-binding molecules and methods of use
HK40083480A (en) Combination therapy of hbv and hdv infection
HK40088755A (zh) Hbv和hdv感染的联合治疗
EA044927B1 (ru) Композиции, содержащие pcsk9-связывающие молекулы, и способы применения
HK1191551A (en) Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides